Who is sponsoring NCT02972450?

NCT02972450 is sponsored by ANRS, Emerging Infectious Diseases.

What drugs are being tested in NCT02972450?

Interventions in NCT02972450: GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine, GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine+ Vedolizumab, Vedolizumab 300 MG [Entyvio], Placebo.

What condition does NCT02972450 study?

NCT02972450 studies HIV-1-infection.

Is NCT02972450 still recruiting?

NCT02972450 is currently terminated. Last updated 29 August 2019.

Last reviewed 2019-08-29 · How we verify

NCT02972450: EHVAT01

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An HIV Vaccine Trial in Individuals Who Started ART During Primary or Chronic Infection

Terminated Phase 1, PHASE2 Last updated 29 August 2019

What this trial tests

Phase 1, PHASE2 trial testing GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine in HIV-1-infection in 1 participant. Terminated before completion.

Timeline

20 February 2019

Primary endpoint
11 July 2019

11 July 2019

Quick facts

Lead sponsor	ANRS, Emerging Infectious Diseases
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	1
Start date	20 February 2019
Primary completion	11 July 2019
Estimated completion	11 July 2019
Sites	2 locations across United Kingdom, Switzerland

Drugs / interventions tested

GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine — full drug profile →
GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine+ Vedolizumab — full drug profile →
Vedolizumab 300 MG [Entyvio]
Placebo

Conditions studied

HIV-1-infection — all drugs for HIV-1-infection →

Sponsor

ANRS, Emerging Infectious Diseases — full company profile →

Who can join

Adults 18 to 65, any sex, with HIV-1-infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

EVHA T01 is an international, phase I/II, multicentre, multi-stage, double-blind study that will evaluate at least three experimental arms compared to placebo control in HIV-1 infected participants to see if one or more has a clinically relevant impact on the control of viral replication.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

The Incorporation of Host Proteins into the External HIV-1 Envelope.
Burnie J, Guzzo C. · · 2019 · cited 56× · PMID 30669528 · DOI 10.3390/v11010085
An update of the recombinant protein expression systems of Cyanovirin-N and challenges of preclinical development.
Lotfi H, Lotfi H, Sheervalilou R, Zarghami N. · · 2018 · cited 16× · PMID 29977835 · DOI 10.15171/bi.2018.16
Comparison of the integrin α4β7 expression pattern of memory T cell subsets in HIV infection and ulcerative colitis.
Wittner M, Schlicker V, Libera J, Bockmann JH, et al · · 2019 · cited 13× · PMID 31356607 · DOI 10.1371/journal.pone.0220008

Verify or expand the search:

Other recruiting trials for HIV-1-infection

Currently open trials in the same condition.

NCT07293559 — Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States · recruiting
NCT06919016 — A Study to Evaluate the Safety and Immunogenicity of the V3-region Directed Immunogens DV700P-RNA Followed by DV701B1.1- · Phase 1 · active not recruiting
NCT06554717 — Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV · Phase 2 · recruiting
NCT06774872 — Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Succes · Phase 2 · recruiting
NCT06890988 — Ending the Epidemic Interventions in the Dental Setting - UH3 · NA · recruiting

Other ANRS, Emerging Infectious Diseases trials

Trials by the same sponsor.

NCT07098481 — Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard Strategy · Phase 4 · not yet recruiting
NCT06913959 — HIV-1 Non-group M in Cameroon : Study of Genotypic and Phylogenetic Diversity (OBSOCAM) · not yet recruiting
NCT07113106 — Dose Escalation Trial of CD40.Pan.CoV Vaccine, Adjuvanted or Not, as a Booster in Adult Healthy Volunteers · Phase 1, PHASE2 · recruiting
NCT05222945 — A Study to Determine the Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Pa · NA · not yet recruiting
NCT06522256 — Identification of Molecular Signatures of High-risk Oncogenic HPV and Study of Their Associations With the Presence of H · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02972450 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ANRS, Emerging Infectious Diseases
Last refreshed: 29 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02972450.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing